M2 Macrophage-based Prognostic Nomogram for Gastric Cancer After Surgical Resection: Original Article

Jianwen Hu  
Peking University First Hospital, Department of Surgery

Yongchen Ma  
Peking University First Hospital, Endoscopy Center

Ju Ma  
Peking University First Hospital, Department of Surgery

Yanpeng Yang  
Peking University First Hospital, Department of Surgery

Yingze Ning  
Peking University First Hospital, Department of Surgery

Jing Zhu  
Peking University First Hospital, Department of Surgery

Pengyuan Wang  
Peking University First Hospital, Department of Surgery

Guowei Chen  (✉ guoweichen@263.net)  
Peking University First Hospital, Department of Surgery

Yuncun Liu  
Peking University First Hospital, Department of Surgery

Research

Keywords: gastric cancer, macrophage, nomogram, prognosis

DOI: https://doi.org/10.21203/rs.3.rs-49461/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: A good prediction model is useful to accurately predict patient prognosis. Tumor–node–metastasis (TNM) staging often cannot accurately predict prognosis when used alone. Some researchers have shown infiltration of M2 macrophages in many tumors, which indicates poor prognosis. This approach has the potential to predict prognosis more accurately when used in combination with TNM staging. The present study aimed to develop and validate a nomogram to predict survival in patients with gastric cancer by combining TNM staging and the degree of M2 macrophage infiltration.

Methods: Patients undergoing curative resection for gastric cancer between 2008 and 2013 at our hospital were enrolled and assigned into either the training set or the validation set. M2 macrophage markers were evaluated by immunohistochemical staining. A stepwise method was applied to screen variables associated with patient survival time, and a nomogram was constructed to predict patient survival. Concordance index, calibration curve, and decision curve analysis were used to evaluate the discrimination, calibration, and clinical benefit of the model.

Results: A multivariate analysis demonstrated that CD163 expression, TNM staging, age, and gender were independent risk factors for overall survival. Thus, these parameters were assessed to develop the nomogram. In the training, validation, and overall datasets, the concordance index was >0.6. The model showed a high degree of discrimination in all three datasets. The five-year survival calibration curves were a very good fit with standard curves in all three datasets, and the model demonstrated good clinical benefit. The prognostic abilities had threshold probabilities of 10%–38% for one-year survival, 10%–75% for three-year survival, and 35%–80% for five-year survival.

Conclusions: We combined CD163 expression in macrophages, TNM staging, age, and gender to develop a nomogram to predict five-year overall survival after curative resection for gastric cancer. This model has the potential to provide further diagnostic and prognostic value for patients with gastric cancer.

Background

More than one million new cases and 783,000 deaths from gastric cancer occurred in 2018. Gastric cancer is the third leading cause of cancer death. The degree of tumor invasiveness, number of positive lymph nodes, and distant metastasis are important factors influencing the prognosis of patients with gastric cancer. As the concept of precision medicine gains popularity, we need to more comprehensively explore the factors that influence and predict the prognosis of patients with gastric cancer.

Emerging studies have highlighted that macrophages are important regulators of therapeutic responses and tumor progression, including proliferation, invasion, and apoptosis. Macrophages are usually of two different subtypes: M1 and M2. M1 macrophages secrete pro-inflammatory cytokines that suppress pathogenic infection and fight against malignancy. M1 macrophage surface markers include the human leukocyte antigen DR isotype (HLA-DR) and nitric oxide synthase. M2 macrophages secrete various anti-inflammatory molecules that can inhibit the immune system and promote tumor angiogenesis,
proliferation, invasion, and metastasis, and prevent apoptosis.\textsuperscript{5,10,11} M2 macrophage surface markers include CD163, Stabilin-1, and CD206.\textsuperscript{4,9,10}

Although some studies have explored the correlation between intertumoral macrophages and prognosis,\textsuperscript{2–5} the results were heterogeneous. Based on the characteristics of the immune state of polarized macrophages, immune status can provide a stratification method to more accurately predict prognosis. Combining the macrophage status with a tumor-cell centered stratification system provides a more precise prognostic prediction.

An alignment diagram, also known as a nomogram, is based on multivariate regression analysis. Nomograms integrate multiple forecast indicators and use line segments with scales according to a certain parameter drawn on the same plane to express the relationship among variables in a prediction model. Currently, nomograms are widely applied in major types of cancer.\textsuperscript{6–11} In addition, nomograms are preferred compared with traditional staging systems for many types of cancer. It is because of the intuitive and easy-to-understand features of nomograms that they have gradually received more and more attention in medical research and clinical practice. Thus, the value of nomograms to predict tumor prognosis is promising.\textsuperscript{9,12}

This study aimed to create a postoperative survival model for patients with cancer to predict survival time after resection and to simultaneously explore the prognostic value of macrophage markers using gastric cancer samples. We used a nomogram to transform the complex regression equation into a visual graph, making the results of the prediction model more readable and convenient for evaluation.

**Methods**

**Clinical specimens and study design**

A total of 112 patients with primary gastric cancer who underwent standard gastrectomy with lymph node dissection from 2008 to 2013 at Peking University First Hospital were enrolled. All patients underwent regular follow up for 7–10 years. Patients were observed until October 2019. Patients undergoing neoadjuvant treatment before surgery were excluded. The pathological diagnostic results were confirmed by two independent gastroenterology pathology doctors, and the gastric cancer classifications were made based on the 8\textsuperscript{th} TNM staging classification for gastric cancer. The clinicopathological characteristics of the 112 patients are shown in Supplementary Table 1. The study was approved by the Peking University First Hospital Biomedical Research Ethics Committee (No. 2017-37). All patients enrolled in the study provided written informed consent.

Clinical information, expression of macrophage markers, and follow-up information from 2008 to 2011 (total of 67 patients) were divided into the training set, and stepwise regression was used to screen the most streamlined clinically meaningful indicators to build a prognostic survival forecasting model. At the same time, clinical information of patients from 2011 to 2013 (total of 45 patients) was used as the
validation set. The value of postoperative survival prediction in patients with gastric cancer was evaluated in the training, validation, and overall datasets from the viewpoints of discrimination (concordance index), calibration, and social benefits (net benefit). A study design flow chart is shown as follows.

**Immunohistochemistry**

We performed immunohistochemical staining for macrophage markers on all tumor tissues obtained from patients. Murine anti-human CD68 (1:200; Santa Cruz Biotechnology, CA, USA), murine anti-human Stabilin-1 (1:250; Santa Cruz Biotechnology), and rabbit anti-human CD163 (1:1000; Abcam, Cambridge, England) antibodies were used to confirm the position of macrophages with respect to cancer tissues. Horseradish peroxidase-conjugated goat anti-rabbit and anti-murine IgG (Zsgb Bio, Beijing, China) were used as secondary antibodies. Macrophage morphology and spatial distribution were assessed by two independent pathologists blinded to patients’ information. A computerized imaging system, including an Olympus DP71 camera and Olympus BX51 microscope, was used to evaluate staining. To ensure homogeneity and representativeness, we scanned immunohistochemistry sections at a high magnification (×400) and captured five independent microscopic fields. The same settings were applied for each image capture. ImagePro Plus version 10.0 (Media Cybernetics, Bethesda, MD, USA) was used to measure the density of macrophage makers. The median relative density was used as the cut-off value for high and low expression. We measured the integrated optical density of all markers that stained positive in each image. We then calculated the ratio of integrated optical density to the total area of each image to obtain the relative density. Results were obtained by calculating the average density of five microscopic fields.

**Statistical analysis**

Stepwise regression algorithms were used to filter variables and build several Cox regression models using Stata for Windows (Stata Corp, TX, USA). We performed a univariate analysis to identify potential risk factors. A P value of ≤0.2 was used to select variables for the model. A multivariate analysis was performed to confirm the best-fit model after potential risk factor selection. We used a Cox regression model to select variables to construct a prediction model. We identified the Akaike information criterion (AIC) of these models, selected the variable with the lowest AIC value for the prediction model, and considered the practical clinical significance of the included variables. A nomogram was constructed based on a multivariate Cox regression analysis for further analysis. We used the likelihood ratio test to apply forward stepwise selection with AIC as the stopping rule. Discrimination was evaluated using the concordance index, and the calibration curve was evaluated using the unreliability U test. The rms package was used for the nomogram and calibration curve in RStudio version 3.5.1 (R Foundation for Statistical Computing, Oakland, New Zealand). To evaluate the clinical benefit of the diagnostic model, a
decision curve analysis plot was developed. The net benefit of making the decision was measured using the following formula:

\[
\text{Net benefit} = \frac{\text{True positives}}{n} - \frac{\text{Pt}}{1 - \text{Pt}} \times \frac{\text{False positives}}{n}
\]

where \( n \) is the total number of patients and \( \text{Pt} \) is a given threshold probability. Decision Curve Analysis quantified the net benefits at different threshold probabilities in the validation set to determine the clinical usefulness of the nomogram.\textsuperscript{15, 16} All statistical analyses noted above were two-sided, and \( P \leq 0.05 \) was considered statistically significant. Stata 15.0 for Windows was applied to carry out the calculation.

The correlation between macrophage marker expression and clinicopathology was evaluated using the \( \chi^2 \) test for categorical data, the Mann–Whitney U test for continuous and ordinally distributed data, and the Kruskal–Wallis test and Fisher’s exact test for ranked ordinal data. We performed a Kaplan–Meier analysis to calculate the survival duration and used the Breslow test (generalized Wilcoxon test) to analyze the significance between groups. The log-rank test was applied to compare survival between subgroups. A one-sample Kolmogorov-Smirnov test was used to test for normality. A multivariate analysis was performed using the stepwise Cox regression model. Variables with a \( P \) value of \( \leq 0.2 \) in the univariate analysis were included in the multivariate regression models. Analysis of Cox regression was employed to compute multivariate hazard ratios and 95% confidence intervals. The results of these tests were analyzed using SPSS version 24.0 (IBM Corp, Armonk, NY, USA). All statistical tests were two-tailed.

**Results**

**Macrophage marker expression**

We applied immunohistochemical methods to observe macrophage subtypes, distribution, and density in tumor areas in samples from patients with gastric cancer. The results showed that CD68, HLA-DR, and CD163 were expressed in the cell membrane and cytoplasm. Macrophages were mostly distributed around tumor cell clusters in dense tumor tissues and were scattered in loose tumor tissue. CD68 and CD163 were occasionally positive in tumor tissues from some patients. The degree of expression of different macrophage markers (CD68 for all macrophages, HLA-DR for M1 macrophages, and CD163 for M2 macrophages) is shown in Figures 1A–C. The density of macrophage infiltration in the tumor nests was varied.

**Risk factors for overall survival**

A univariate survival analysis indicated that the following clinical factors \( (P = 0.026) \) were significantly correlated with a reduction in overall survival: T stage \( (P < 0.001) \), N stage \( (P < 0.001) \), M stage \( (P < 0.001) \), nerve invasion \( (P = 0.014) \), cancer embolus \( (P = 0.039) \), and CD163 positive macrophage density
A multivariate analysis demonstrated that age ($P = 0.008$), T stage ($P < 0.001$), M stage ($P < 0.001$), and CD163 positive macrophage density ($P = 0.043$) were independent risk factors for overall survival (Supplementary Table 2). Therefore, infiltration of M2 macrophages in gastric cancer has the potential to predict prognosis.

**Clinicopathological characteristics of the training and validation sets**

Table 1 shows the clinical features and expression of macrophage markers, which were collected and included in stepwise screening. To facilitate a comprehensive understanding of the data, TNM stages are also shown in the table, but this variable was not included in the stepwise method to avoid repetition. Sixty-seven samples were included in the training set, which were collected from patients with an average age of $63.7 \pm 12.1$ years and a median age of 64.0 years. Forty-five samples were obtained from patients in the validation set with an average age of $61.7 \pm 12.9$ years and a median age of 65.0 years. The median survival times of patients in the training and validation sets were 73.0 and 49.0 month, respectively, and the five-year survival rates were 52.2% and 46.7%, respectively.

Multivariate analyses with procedure forward, backward, and stepwise were performed to establish the best-fit model in the training set. After calculating and comparing the AIC values of these models, we selected the model with the lowest AIC value (AIC = 238.1). As shown in Table 2, the prediction model included five variables (age, T stage, N stage, M stage, and CD163 expression level) with practical clinical significance.
Table 1
Clinicopathological characteristics of the training and validation sets.

| Factors                              | Training | Validation |
|--------------------------------------|----------|------------|
|                                      | No.      | %          | No.      | %          |
| Mean age (years)                     |          |            |          |            |
| Age (mean ± standard deviation, years) | 63.7±12.1 | 61.7±12.9  |
| Gender                               |          |            |          |            |
| Female                               | 17       | 25.4       | 11       | 24.4       |
| Male                                 | 50       | 74.6       | 34       | 75.6       |
| Tumor Size (cm)                      |          |            |          |            |
| ≤5                                   | 30       | 44.8       | 10       | 22.2       |
| ≥5                                   | 37       | 55.2       | 35       | 77.8       |
| Pathological type                    |          |            |          |            |
| Adenocarcinoma                       | 41       | 61.2       | 29       | 64.4       |
| · Mucinous carcinoma                 | 4        | 6.0        | 2        | 4.4        |
| · Silver ring cell carcinoma         | 22       | 32.8       | 14       | 31.1       |
| Bormann classification               |          |            |          |            |
| I                                    | 4        | 6.0        | 2        | 4.4        |
| II                                   | 30       | 44.8       | 9        | 20.0       |
| III                                  | 28       | 41.8       | 29       | 64.4       |
| IV                                   | 5        | 7.5        | 5        | 11.1       |
| Grade                                |          |            |          |            |
| Poorly                               | 51       | 76.1       | 37       | 82.2       |
| Moderate                             | 13       | 19.4       | 8        | 17.8       |
| Good                                 | 3        | 4.5        | 0        | 0          |
| T Stage                              |          |            |          |            |
| T1                                   | 5        | 7.5        | 0        | 0          |
| T2                                   | 5        | 7.5        | 0        | 0          |
| T3                                   | 32       | 47.8       | 18       | 40         |
| T4                                   | 25       | 37.3       | 27       | 60         |
| N Stage |  |  |  |  |
|---------|---|---|---|---|
| N0      | 19 | 28.4 | 5 | 11.1 |
| N1      | 8 | 11.9 | 8 | 17.8 |
| N2      | 14 | 20.9 | 13 | 28.9 |
| N3      | 26 | 38.8 | 19 | 42.4 |
| M Stage |  |  |  |  |
| No      | 60 | 89.6 | 41 | 91.1 |
| Yes     | 7 | 10.4 | 4 | 8.9 |
| TNM classification |  |  |  |  |
| No      | 5 | 7.5 | 0 | 0 |
| Yes     | 5 | 7.5 | 0 | 0 |
| No      | 32 | 47.7 | 18 | 40.0 |
| Yes     | 25 | 37.3 | 27 | 60.0 |
| Nerve invasion |  |  |  |  |
| No      | 35 | 52.2 | 12 | 26.7 |
| Yes     | 32 | 47.8 | 33 | 73.3 |
| Cancer embolus |  |  |  |  |
| No      | 51 | 76.1 | 27 | 60 |
| Yes     | 16 | 23.9 | 18 | 40 |
| CD68 expression |  |  |  |  |
| Low     | 34 | 50.7 | 22 | 48.9 |
| High    | 33 | 49.3 | 23 | 51.1 |
| HLA-DR expression |  |  |  |  |
| Low     | 28 | 41.8 | 28 | 62.2 |
| High    | 39 | 58.2 | 17 | 37.8 |
| CD163 expression |  |  |  |  |
| Low     | 34 | 50.7 | 22 | 48.9 |
| High    | 33 | 49.3 | 23 | 51.1 |
Table 2
Predictors of overall survival in patients with gastric cancer.

| Variable      | Coef.  | Stderr | Z     | P       | 95%CI     |
|---------------|--------|--------|-------|---------|-----------|
| Gender        | 1.354  | 0.555  | 2.44  | 0.015   | 0.266     |
| Age           | 0.033  | 0.018  | 1.84  | 0.066   | -0.002    |
| T stage       | 1.219  | 0.335  | 3.64  | 0.000   | 0.564     |
| N stage       | 0.251  | 0.164  | 1.53  | 0.127   | -0.710    |
| M stage       | 1.849  | 0.517  | 3.58  | 0.000   | 0.836     |
| CD163 Expression | 0.552  | 0.398  | 1.39  | 0.165   | -0.228    |

Prognostic nomogram for overall survival in patients with gastric cancer

The variables included in the prediction model were age, gender, TNM stage, and density of CD163 expression. The basic principle of the nomogram is to construct multi-factor Cox regression according to the contribution of each influencing factor in the model to the outcome variables (three- and five-year survival after gastric resection). The scores of each influencing factor were then summed to obtain the total score, and the individual outcomes were calculated based on the functional conversion relationship between the total score and the probability (the predicted value) of three- and five-year survival events.

Performance of the model in the training, validation, and overall datasets

Concordance index and calibration plot

Concordance index (c-index) plots are shown in Figures 3A–C. We applied the constructed model to the training set, validation set, and the overall dataset to judge the discrimination of this model to predict survival time during the follow-up period (0–120 months). The model showed a high degree of discrimination in all three datasets (c-index, >0.6 from 12 to 120 months).

The calibration curve graphically represents the correlation between the predicted probabilities and the observed outcome frequencies. The degree of conformity between the calibration curve and the standard curve represents the degree of calibration. Calibration of three- and five-year survival in the three datasets is shown in Figures 3D–H. The five-year survival calibration curves of this model were a very good fit with
the standard curve in all three datasets, and three-year survival calibration curves were only good fit with
the standard curve in training and overall datasets.

Decision curve analysis plots

The decision curves for the model are illustrated in Figure 4. The clinical impact of the prediction
model to identify individuals for survival prediction was observed at thresholds of $\geq 18\%$ for three-year
survival and $\geq 30\%$ for five-year survival. The model was useful between threshold probabilities of 10%
and 75\% for three-year survival and 35\% and 80\% for five-year survival.

Relationship between macrophage polarization and
clinicopathological features

The correlation between CD68, the expression of other molecules, and clinicopathological features is
shown in Supplementary Table 1. CD163 staining was correlated with the invasion of lymph nodes ($P =
0.002$), TNM stage ($P = 0.017$), and tumor size ($P = 0.049$). There was no significant difference in the
density of CD68 and HLA-DR among samples of different TNM stages (Figures 5A and 5B). The density
of CD163 in M2 macrophages was higher in TNM stage III–IV compared with TNM stage I–II (Figure 5B).
There was no significant difference in the density distribution of other types of macrophage between
different TNM stages in this study.

Prognostic value of macrophage polarization

A Kaplan–Meier analysis was performed on the overall dataset. High CD163 expression was related to
reduced survival (Figure 6A; $P = 0.007$), whereas CD68 and HLA-DR staining had no obvious correlation
with overall survival (Figure 6A; $P = 0.324$ and $P = 0.775$, respectively).

High CD163 expression indicated a shorter survival time after resection in TNM stage I–II (Figure 6B; $P =
0.039$), which is consistent with the conclusions of others.\textsuperscript{17-19} CD68 showed no significant relationship
with overall survival in patients classified as TNM stage I–II or TNM stage III–IV (Figures 6A–C; $P = 0.324$,$P = 0.379$, and $P = 0.304$, respectively). Zhang’s research came to the same conclusion.\textsuperscript{17} Similarly, HLA-
DR showed no evident relationship with overall survival in patients in the early and advanced stages
(Figures 6A–C; $P = 0.775$, $P = 0.666$, and $P = 0.667$, respectively). The results do not illustrate that total
macrophage and M1 macrophage infiltration had prognostic significance, which is different from other
studies.\textsuperscript{17, 20} These results only suggest that M2 makers, but not M1 or macrophage markers, offer
prognostic information in different TNM stages.

Discussion
The type and function of immune cells play an important role in tumor development. Inflammation in the tumor microenvironment is an important manifestation of malignant tumors, and macrophages are the main inflammatory cells in the tumor microenvironment. Monocytes are derived from CD34 primary myeloid progenitor cells in the bone marrow, are distributed in the blood circulation, and enter tissues to differentiate into different macrophage subtypes. M2 macrophages indirectly promote tumor cell growth by secreting interleukin-10 and transforming growth factor-β, while inhibiting immune response cells in the microenvironment. However, the impact of macrophage infiltration in the tumor microenvironment is still controversial. Some researchers have shown that massive infiltration of tumor tissues causes excessive macrophages to participate in the inflammatory response, providing an environment that supports tumor growth and metastasis.

In this study, we explored the prognostic significance of M1/M2 macrophage markers in patients with gastric cancer and found that an increase in M2 macrophages was the main reason for malignant development of tumors, while the overall density of macrophages and the density of M1 macrophages showed no effect on the prognosis of patients with gastric cancer. Univariate and multivariate Cox regression analyses demonstrated that age, TNM stage, and CD163 were independent risk factors for overall survival. Therefore, infiltration of M2 macrophages in gastric cancer has the potential to predict prognosis, which is consistent with the results reported by other researchers in other tumor types.

The TNM staging system is the most common method for predicting patient prognosis. The incidence of gastric cancer and the mortality associated with gastric cancer are higher in males than in females. Younger patients are generally recognized to have longer overall survival compared with older patients with gastric cancer. At the same time, a Korean study showed that in patients with stage I–II gastric cancer, the < 50-year age group was associated with a significantly lower proportion of cancer-specific mortality compared with the 70–79-year age group. These studies suggest that if TNM staging is combined with M2 marker expression, age, and gender, this would greatly improve the prognostic ability of postoperative survival.

In the present study, we established a nomogram to evaluate the survival probability of patients after gastric cancer resection. We incorporated the recognized TNM staging system and the degree of M2 infiltration, age, and gender into this model, increasing the predictive accuracy of the model. Considerable differences in survival were observed even in patients with the same stage of gastric cancer. When the constructed model was applied to the validation and overall datasets, a high degree of discrimination and calibration were verified. And it was equipped with a high clinical benefit rate. The postoperative survival prediction model has good extrapolation potential.

The correlation analysis between macrophage polarization status and clinicopathological stage in gastric cancer showed that the density of CD163-positive macrophages was higher in patients with TNM III–IV compared with patients with TNM stage I–II. The density differences among other types of macrophage towards TNM staging did not reach significance in the present study. The prognostic survival analysis demonstrated that high expression of CD163 was related to reduced overall survival after resection in
patients with early-stage tumors, which is consistent with the conclusions of others.\textsuperscript{17–19} These results fully explain why infiltration of M2 macrophages can predict prognosis and survival time when combined with TNM staging.

The results of the present study might provide evidence for clinicians to stratify patients with different prognoses. Due to the limitations of single-center retrospective studies, more multi-center studies are needed to further validate the effects of macrophage infiltration into the tumor microenvironment and to determine the efficacy of the M2 macrophage-based nomogram on the prognosis of patients with gastric cancer.

\textbf{Conclusion}

In conclusion, we combined CD163 expression with TNM staging, age, and gender to construct a nomogram that has the potential to be used as a useful prognostic tool for patients with gastric cancer. An increase in M2 macrophages predicts a shorter survival time in patients after surgery for gastric cancer. This study provides a theoretical basis and highlights potential targets for immunotherapy in patients with gastric cancer.

\textbf{Abbreviations}

TAM: Tumor-associated macrophage;

M1: M1-type tumor-associated macrophage;

M2: M2-type tumor-associated macrophage;

OS: Overall survival;

HRP: Horseradish peroxidase;

PBS: Phosphate-buffered saline;

H&E: Hematoxylin and eosin;

HR: Hazard ratio.

\textbf{Declarations}

\textbf{Ethics approval and consent to participate}

The study was approved by the Peking University First Hospital Biomedical Research Ethics Committee (No.2017-37). All patients connected with this study signed an informed consent agreement.
Consent for publication

We confirm that all the above information is authentic. We have approved the final manuscript and its submission to Journal of Translational Medicine. I agree with the journal's copyright policy.

Availability of data and materials

All data and materials are freely accessible. The data generated or analyzed during this study is included in the article published here.

Competing Interests

The authors declare that they have no competing interests.

Funding

National Science and Technology Major Project of China (2018ZX10723204) supported the completion of this project.

Authors’ contributions

Jianwen Hu and Yongchen Ma participated in the study design, carried out the immunocytochemical staining and analysis, and completed the manuscript. Yanpeng Yang and Yingze Ning performed clinical information collection from patients. Jing Zhu analyzed patient data and Pengyuan Wang performed the statistical analysis. Yucun Liu and Guowei Chen were major contributors to the design of this study and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the National Science and Technology Major Project of China (2018ZX10723204). The authors acknowledge Dingfang Bu and Jianqiang Dong for their technical support in histomorphology staining.

Department

Department of General Surgery, Peking University First Hospital, Beijing 100034, PR China.

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68:394-424.

2. Zhang H, Wang X, Shen Z, Xu J, Qin J, Sun Y. Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015;18:740-50.

3. Lin CN, Wang CJ, Chao YJ, Lai MD, Shan YS. The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression. BMC cancer. 2015;15:128.

4. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. International journal of oncology. 2000;17:445-51.

5. Ohno S, Inagawa H, Dhar DK, et al. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer research. 2003;23:5015-22.

6. Ehdaie B, Theodorescu D. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. European Urology. 2007;52(1):281-282.

7. Karakiewicz PI, Briganti A, Chun FK, et al. Multi-Institutional Validation of a New Renal Cancer-Specific Survival Nomogram. Journal of Clinical Oncology. 2007;25(11):1316-1322.

8. Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679.

9. Kim SI, Song M, Hwangbo S, Lee S, et al. Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer. Cancer Res Treat. 2019;51:1144-55.

10. Song K, Shi X, Wang H, et al. Can a Nomogram Help to Predict the Overall and Cancer-specific Survival of Patients with Chondrosarcoma? Clin Orthop Relat Res. 2018;476:987-96.

11. Dong F, Shen Y, Gao F, et al. Nomograms to Predict Individual Prognosis of Patients with Primary Small Cell Carcinoma of the Bladder. Journal of Cancer. 2018;9:1152-64.

12. Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer. 2010;103(2):402-08.

13. Bertens LC, Moons KG, Rutten FH, van Mourik Y, Hoes AW, Reitsma JB. A nomogram was developed to enhance the use of multinomial logistic regression modeling in diagnostic research. J Clin Epidemiol. 2016;71:51-7.

14. Alba AC, Agoritsas T, Walsh M, et al. Discrimination and Calibration of Clinical Prediction Models: Users’ Guides to the Medical Literature. Jama. 2017;318:1377-84.

15. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565-74.
16. Fitzgerald M, Saville BR, Lewis RJ. Decision Curve Analysis. Jama Journal of the American Medical Association. 2015;313:409-10.

17. Zhang H, Wang X, Shen Z, Xu J, Qin J, Sun Y. Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric Cancer. 2015;18(4):740-750.

18. Park JY, Sung JY, Lee J, et al. Polarized CD163+ tumor-associated macrophages are associated with increased angiogenesis and CXCL12 expression in gastric cancer. Clinics and research in hepatology and gastroenterology. 2015;40:357-65.

19. Kim KJ, Wen XY, Yang HK, Kim WH, Kang GH. Prognostic Implication of M2 Macrophages Are Determined by the Proportional Balance of Tumor Associated Macrophages and Tumor Infiltrating Lymphocytes in Microsatellite-Unstable Gastric Carcinoma. PloS One. 2015;10(12):e0144192.

20. Pantano F, Berti P, Guida F M, et al. The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients. Journal of Cellular & Molecular Medicine. 2014;17(11):1415-1421.

21. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610-618.

22. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.

23. Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J.leukoc.biol. 2001;69:11-20.

24. Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. The mononuclear phagocyte system revisited. J Leukoc Biol. 2002;72(4):621-627.

25. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177(10):7303-7311.

26. Lgars A, Irjala H, Vaittinen S, et al. Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. International Journal of Cancer. 2012;131(4):864-73.

27. Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):58.

28. Moghaddam AS, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization and function in health and disease. J Cell Physiol. 2018;233(9):6425-6440.

29. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71-78.

30. Ariake K, Ueno T, Takahashi M, et al. E-PASS comprehensive risk score is a good predictor of postsurgical mortality from comorbid disease in elderly gastric cancer patients. J Surg Oncol. 2014;109:586-92.
31. Lee J, Kim S, Eun C, et al. Impact of Age on Stage-Specific Mortality in Patients with Gastric Cancer: A Long-Term Prospective Cohort Study. Gastroenterology. 2019;156:S-1026-S-1027.

Figures

Figure 1

The expression of macrophage markers in gastric cancer. A–C. Immunohistochemical staining indicated low and high expression of CD68, HLA-DR, and CD163.
Prognostic nomogram for overall survival of patients with gastric cancer. The total score was the sum of the individual scores for every variable, and the length of the line segment reflected how much the factor contributed to the outcome events. Three- and five-year survival in the nomogram indicated the survival probabilities.
Figure 3

A–C. Concordance index (c-index) plots of the model to predict three- and five-year survival rates in the training, validation, and overall datasets, respectively. D–I. Calibration curves of the model to predict three- and five-year survival rates in the training, validation, and overall datasets, respectively. Actual survival is plotted on the y axis, and the x axis represents the predictive probability of the model.
Figure 4

A–C. Decision curve analysis to predict three-year survival rates in the training, validation, and overall datasets. D–F. Decision curve analysis plots to predict five-year survival rates in the training, validation, and overall datasets.
Figure 5

A and B. Distribution of CD68-, HLA-DR-, and CD163-positive macrophages in different TNM stages.
Figure 6

A–C. Kaplan–Meier survival curves of low and high expression of CD68, HLA-DR, and CD163 in different TNM stages.
Figure 7
A study design flow chart

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- supplementarytable2.docx
- supplementarytable1.docx